- Conditions
- Atherosclerosis, Cardiovascular Disease
- Interventions
- any statin, niacin, Placebo
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypercholesterolaemia
- Interventions
- Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin, Ezetimibe, Cholestyramine, Nicotinic acid, Fenofibrate, Omega-3 fatty acids, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more
- Conditions
- Dyslipidemia
- Interventions
- Atorvastatin, ABT335, ER Niacin
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 18
- States / cities
- Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
- Conditions
- Peripheral Arterial Disease
- Interventions
- Ezetimibe, Niaspan, Statin therapy, Standard care, Aspirin, Clopidogrel, Placebo Niaspan, Placebo Ezetimibe, Percutaneous transluminal angioplasty (PTA)
- Drug · Behavioral · Procedure
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- atorvastatin, simvastatin, ezetimibe, fenofibrate, dextromethorphan, Extended Release Niacin
- Drug
- Lead sponsor
- Aegerion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hypertriglyceridemia
- Interventions
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 80
- States / cities
- Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
- Conditions
- Cardiovascular Diseases
- Interventions
- AMR101, Placebo, Statin therapy
- Drug
- Lead sponsor
- Amarin Pharma Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 8,179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 176
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
- Conditions
- Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
- Interventions
- Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
- Conditions
- Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Niacin ER/Simvastatin Tablets, atorvastatin
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 46
- States / cities
- Anaheim, California • Huntington Park, California • Long Beach, California + 43 more
- Conditions
- Dyslipidemia
- Interventions
- Slo-Niacin, atorvastatin
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington